USP47 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2680022	1.00	20/20
SCHEMBL2680788	1.00	20/20
SCHEMBL2681371	1.00	20/20
SCHEMBL2681865	0.90	20/20
SCHEMBL2680542	0.85	20/20
SCHEMBL2681522	0.83	20/20
SCHEMBL2679816	0.83	20/20
SCHEMBL2680453	0.82	20/20
SCHEMBL2681046	0.82	20/20
SCHEMBL2681028	0.82	20/20
SCHEMBL2681409	0.82	20/20
SCHEMBL2680459	0.82	20/20
SCHEMBL2681045	0.82	20/20
SCHEMBL2681131	0.81	20/20
SCHEMBL2679631	0.81	20/20
SCHEMBL2681879	0.81	20/20
SCHEMBL2681327	0.80	20/20
SCHEMBL2680853	0.80	20/20
SCHEMBL2681215	0.80	20/20
SCHEMBL2681290	0.80	20/20

Clinical trials — most relevant to USP47 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients	nan	UNKNOWN
Using Mobile Technology to Improve Self-Regulation	nan	COMPLETED
The Danish TURNER Cryopreservation Study	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP47 binder may also engage these)

Protein	Name	Similarity
E1C1R4	—	1.000	E1C1R4 →
Q8BY87	—	1.000	Q8BY87 →
Q5U252	—	0.995	Q5U252 →
A1A5G2	—	0.993	A1A5G2 →
Q9R1D7	—	0.975	Q9R1D7 →
O94888	—	0.973	O94888 →
Q5REY7	—	0.972	Q5REY7 →
PRKD1	Serine/threonine-protein kinase D1	0.971	landscape →
Q6IE70	—	0.969	Q6IE70 →
Q3LAC4	—	0.968	Q3LAC4 →
Q6DFZ1	—	0.967	Q6DFZ1 →
NEK10	Serine/threonine-protein kinase Nek10	0.967	landscape →
F1LTE0	—	0.967	F1LTE0 →
Q3KR37	—	0.967	Q3KR37 →
Q504Q3	—	0.967	Q504Q3 →
Q5RDU9	—	0.966	Q5RDU9 →
Q5T6S3	—	0.966	Q5T6S3 →
Q08BT5	—	0.965	Q08BT5 →
Q5RCW6	—	0.965	Q5RCW6 →
Q8WXI2	—	0.964	Q8WXI2 →
Q9ESL4	—	0.964	Q9ESL4 →
Q9P260	—	0.964	Q9P260 →
Q7YQL6	—	0.964	Q7YQL6 →
Q3UGM2	—	0.964	Q3UGM2 →
Q9HCD6	—	0.963	Q9HCD6 →
Q9BZ29	—	0.963	Q9BZ29 →
Q5R372	—	0.963	Q5R372 →
Q148V7	—	0.963	Q148V7 →
Q9WTQ1	—	0.963	Q9WTQ1 →
O75563	—	0.963	O75563 →